• Overall survival, breast cancer-free interval, disease-free interval, distant disease-free survival. [ Time Frame: Event driven. ] [ Designated as safety issue: No ]
• AEs, and laboratory parameters. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

This 2 arm open-label study will evaluate the efficacy and safety of the addition of Avastin (bevacizumab) to standard adjuvant therapy in patients with triple negative breast cancer. Patients will be randomized to receive either standard chemotherapy (anthracycline +/- taxane or taxane only), or standard chemotherapy given concurrently with 1 year of Avastin (5mg/kg/week dosing equivalent i.v.). The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

• Drug: bevacizumab [Avastin]
• Drug: Standard adjuvant chemotherapy

Inclusion Criteria:

• adult patients, >=18 years of age;
• operable primary invasive breast cancer;
• completed definitive loco-regional surgery;
• primary tumor centrally confirmed as triple negative.

Exclusion Criteria:

• locally advanced breast cancers;
• previous breast cancer history;
• clinically significant cardiovascular disease.